Trial Profile

A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Bictegravir; Bictegravir/emtricitabine/tenofovir alafenamide; Emtricitabine/tenofovir alafenamide; Tenofovir alafenamide
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms CALIBRATE
Sponsors Gilead Sciences

06 Mar 2024 Plasma samples with CA resistance mutations from CAPELLA and CALIBRATE studies (n=21) were used for phenotypic characterization of replication-impaired lenacapavir-resistant HIV clinical isolates, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
03 Oct 2023 Status changed from active, no longer recruiting to completed.
02 Jun 2023 Planned End Date changed from 1 Apr 2024 to 1 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com